COMPASS FINANCIAL MANAGEMENT LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.55K	Buy	+694	New	+$2.31K	﹤0.01%	1288

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's RXRX Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 694 shares worth $2.55K. The stake represents ﹤0.01% of the portfolio and ranks #1288 among its holdings.

218 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

COMPASS FINANCIAL MANAGEMENT LLC held 694 shares of Recursion Pharmaceuticals worth $2.55K as of Q2 2026.
Recursion Pharmaceuticals was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #1288 holding.
218 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.